Member Exclusive News

The week in industry: Spinal muscular atrophy treatment gets positive recommendation from NICE

This week: Vertex Pharmaceuticals and Kymera Therapeutics (both MA, USA) enter into a four-year collaboration to develop protein targeted therapies, the US FDA approves the first combination PD-L1 therapy for advanced renal cell carcinoma and Vaccitech (Berlin, Germany) is granted access to ProBioGen’s (Oxford, UK) vaccine manufacturing production platform.

Go to the profile of RxNet
May 16, 2019

Please sign in or register for FREE

No comments yet.